Hiroyuki Sorimachi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hiroyuki Sorimachi has a total of 483 co-authors. Here are the top co-authors by number of shared publications:
Koichi Suzuki
61 shared publicationsYasuko Ono
Calpain Project, Department of Basic Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Setagaya-ku, Tokyo, Japan
40 shared publicationsShoichi Ishiura
Department of Life Sciences, Graduate School of Arts and Sciences, The University of Tokyo 3-8-1 Komaba, Meguro-ku, Tbkyo 153-8902, Japan
30 shared publicationsShoji Hata
From the ‡Calpain Project, Department of Advanced Science for Biomolecules, and
27 shared publicationsNaoko Doi
From the ‡Calpain Project, Department of Advanced Science for Biomolecules, and
15 shared publicationsK Suzuki
13 shared publications
Latest Publications
- Open Access
- 21 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-16
The UFM1 system regulates ER-phagy through the ufmylation of CYB5R3
Protein modification by ubiquitin-like proteins (UBLs) amplifies limited genome information and regulates diverse cellular processes, including translation, autophagy and antiviral pathways. Ubiquitin-fold modifier 1 (UFM1) is a UBL covalently conjugated with intracellular proteins through ufmylation, a reaction analogous to ubiquitylation. Ufmylation is involved in processes such as endoplasmic reticulum (ER)-associated protein degradation, ribosome-associated protein quality control at the ER and ER-phagy. However, it remains unclear how ufmylation regulates such distinct ER-related functions. Here we identify a UFM1 substrate, NADH-cytochrome b5 reductase 3 (CYB5R3), that localizes on the ER membrane. Ufmylation of CYB5R3 depends on the E3 components UFL1 and UFBP1 on the ER, and converts CYB5R3 into its inactive form. Ufmylated CYB5R3 is recognized by UFBP1 through the UFM1-interacting motif, which plays an important role in the further uyfmylation of CYB5R3. Ufmylated CYB5R3 is degraded in lysosomes, which depends on the autophagy-related protein Atg7- and the autophagy-adaptor protein CDK5RAP3. Mutations ofCYB5R3and genes involved in the UFM1 system cause hereditary developmental disorders, and ufmylation-defectiveCyb5r3knock-in mice exhibit microcephaly. Our results indicate that CYB5R3 ufmylation induces ER-phagy, which is indispensable for brain development.
- 21 December 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-16
Open AccessThe UFM1 system regulates ER-phagy through the ufmylation of CYB5R3
Protein modification by ubiquitin-like proteins (UBLs) amplifies limited genome information and regulates diverse cellular processes, including translation, autophagy and antiviral pathways. Ubiquitin-fold modifier 1 (UFM1) is a UBL covalently conjugated with intracellular proteins through ufmylation, a reaction analogous to ubiquitylation. Ufmylation is involved in processes such as endoplasmic reticulum (ER)-associated protein degradation, ribosome-associated protein quality control at the ER and ER-phagy. However, it remains unclear how ufmylation regulates such distinct ER-related functions. Here we identify a UFM1 substrate, NADH-cytochrome b5 reductase 3 (CYB5R3), that localizes on the ER membrane. Ufmylation of CYB5R3 depends on the E3 components UFL1 and UFBP1 on the ER, and converts CYB5R3 into its inactive form. Ufmylated CYB5R3 is recognized by UFBP1 through the UFM1-interacting motif, which plays an important role in the further uyfmylation of CYB5R3. Ufmylated CYB5R3 is degraded in lysosomes, which depends on the autophagy-related protein Atg7- and the autophagy-adaptor protein CDK5RAP3. Mutations ofCYB5R3and genes involved in the UFM1 system cause hereditary developmental disorders, and ufmylation-defectiveCyb5r3knock-in mice exhibit microcephaly. Our results indicate that CYB5R3 ufmylation induces ER-phagy, which is indispensable for brain development.
- 29 March 2018
- Published by Science Impact, Ltd. in Impact
- Vol. 2018 (2) , 74-76
Elucidation of the molecular mechanism of disease development due to calpain dysfunction – CALPAIN
The CALPAIN project aims to unravel the complexity of calpain molecules and, in turn, use their discoveries to generate effective drugs and therapies for calpain-related diseases. Along with studying the basic structure and function of a calpain, researchers are working to unravel the molecular mechanisms behind calpain-related diseases. By discovering the pathology of these diseases, members of the CALPAIN project can aid in the development of novel strategies for predicting, preventing, diagnosing and treating various disorders. In an effort to further scientific understanding of calpains and their vital biological roles, the CALPAIN project was established within the Tokyo Metropolitan Institute of Medical Science in Japan. Led by Department Head Dr Hiroyuki Sorimachi, the CALPAIN project's goals include analysing the mechanisms of calpains at a molecular level; clarifying their physiological functions; analysing diseases marked by calpain deficiency using genetically-modified mice; and developing future diagnosis and treatment plans for calpain-related diseases.
- 29 March 2018
- Published by Science Impact, Ltd. in Impact
- Vol. 2018 (2) , 74-76
Elucidation of the molecular mechanism of disease development due to calpain dysfunction – CALPAIN
The CALPAIN project aims to unravel the complexity of calpain molecules and, in turn, use their discoveries to generate effective drugs and therapies for calpain-related diseases. Along with studying the basic structure and function of a calpain, researchers are working to unravel the molecular mechanisms behind calpain-related diseases. By discovering the pathology of these diseases, members of the CALPAIN project can aid in the development of novel strategies for predicting, preventing, diagnosing and treating various disorders. In an effort to further scientific understanding of calpains and their vital biological roles, the CALPAIN project was established within the Tokyo Metropolitan Institute of Medical Science in Japan. Led by Department Head Dr Hiroyuki Sorimachi, the CALPAIN project's goals include analysing the mechanisms of calpains at a molecular level; clarifying their physiological functions; analysing diseases marked by calpain deficiency using genetically-modified mice; and developing future diagnosis and treatment plans for calpain-related diseases.
- 11 November 2016
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 15 (12) , 854-876
Calpain research for drug discovery: challenges and potential
Calpains are a family of proteases that were scientifically recognized earlier than proteasomes and caspases, but remain enigmatic. However, they are known to participate in a multitude of physiological and pathological processes, performing 'limited proteolysis' whereby they do not destroy but rather modulate the functions of their substrates. Calpains are therefore referred to as 'modulator proteases'. Multidisciplinary research on calpains has begun to elucidate their involvement in pathophysiological mechanisms. Therapeutic strategies targeting malfunctions of calpains have been developed, driven primarily by improvements in the specificity and bioavailability of calpain inhibitors. Here, we review the calpain superfamily and calpain-related disorders, and discuss emerging calpain-targeted therapeutic strategies.
- 11 November 2016
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 15 (12) , 854-876
Calpain research for drug discovery: challenges and potential
Calpains are a family of proteases that were scientifically recognized earlier than proteasomes and caspases, but remain enigmatic. However, they are known to participate in a multitude of physiological and pathological processes, performing 'limited proteolysis' whereby they do not destroy but rather modulate the functions of their substrates. Calpains are therefore referred to as 'modulator proteases'. Multidisciplinary research on calpains has begun to elucidate their involvement in pathophysiological mechanisms. Therapeutic strategies targeting malfunctions of calpains have been developed, driven primarily by improvements in the specificity and bioavailability of calpain inhibitors. Here, we review the calpain superfamily and calpain-related disorders, and discuss emerging calpain-targeted therapeutic strategies.
- 15 August 2016
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 126 (9) , 3417-3432
Calpain-6 confers atherogenicity to macrophages by dysregulating pre-mRNA splicing
Macrophages contribute to the development of atherosclerosis through pinocytotic deposition of native LDL–derived cholesterol in macrophages in the vascular wall. Inhibiting macrophage-mediated lipid deposition may have protective effects in atheroprone vasculature, and identifying mechanisms that potentiate this process may inform potential therapeutic interventions for atherosclerosis. Here, we report that dysregulation of exon junction complex–driven (EJC-driven) mRNA splicing confers hyperpinocytosis to macrophages during atherogenesis. Mechanistically, we determined that inflammatory cytokines induce an unconventional nonproteolytic calpain, calpain-6 (CAPN6), which associates with the essential EJC-loading factor CWC22 in the cytoplasm. This association disturbs the nuclear localization of CWC22, thereby suppressing the splicing of target genes, including those related to Rac1 signaling. CAPN6 deficiency in LDL receptor–deficient mice restored CWC22/EJC/Rac1 signaling, reduced pinocytotic deposition of native LDL in macrophages, and attenuated macrophage recruitment into the lesions, generating an atheroprotective phenotype in the aorta. In macrophages, the induction of CAPN6 in the atheroma interior limited macrophage movements, resulting in a decline in cell clearance from the lesions. Consistent with this finding, we observed that myeloid CAPN6 contributed to atherogenesis in a murine model of bone marrow transplantation. Furthermore, macrophages from advanced human atheromas exhibited increased CAPN6 induction and impaired CWC22 nuclear localization. Together, these results indicate that CAPN6 promotes atherogenicity in inflamed macrophages by disturbing CWC22/EJC systems.
- 15 August 2016
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 126 (9) , 3417-3432
Calpain-6 confers atherogenicity to macrophages by dysregulating pre-mRNA splicing
Macrophages contribute to the development of atherosclerosis through pinocytotic deposition of native LDL–derived cholesterol in macrophages in the vascular wall. Inhibiting macrophage-mediated lipid deposition may have protective effects in atheroprone vasculature, and identifying mechanisms that potentiate this process may inform potential therapeutic interventions for atherosclerosis. Here, we report that dysregulation of exon junction complex–driven (EJC-driven) mRNA splicing confers hyperpinocytosis to macrophages during atherogenesis. Mechanistically, we determined that inflammatory cytokines induce an unconventional nonproteolytic calpain, calpain-6 (CAPN6), which associates with the essential EJC-loading factor CWC22 in the cytoplasm. This association disturbs the nuclear localization of CWC22, thereby suppressing the splicing of target genes, including those related to Rac1 signaling. CAPN6 deficiency in LDL receptor–deficient mice restored CWC22/EJC/Rac1 signaling, reduced pinocytotic deposition of native LDL in macrophages, and attenuated macrophage recruitment into the lesions, generating an atheroprotective phenotype in the aorta. In macrophages, the induction of CAPN6 in the atheroma interior limited macrophage movements, resulting in a decline in cell clearance from the lesions. Consistent with this finding, we observed that myeloid CAPN6 contributed to atherogenesis in a murine model of bone marrow transplantation. Furthermore, macrophages from advanced human atheromas exhibited increased CAPN6 induction and impaired CWC22 nuclear localization. Together, these results indicate that CAPN6 promotes atherogenicity in inflamed macrophages by disturbing CWC22/EJC systems.
- Open Access
- 1 April 2016
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 15 (4) , 1262-1280
Predictions of Cleavability of Calpain Proteolysis by Quantitative Structure-Activity Relationship Analysis Using Newly Determined Cleavage Sites and Catalytic Efficiencies of an Oligopeptide Array
- 1 April 2016
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 15 (4) , 1262-1280
Open AccessPredictions of Cleavability of Calpain Proteolysis by Quantitative Structure-Activity Relationship Analysis Using Newly Determined Cleavage Sites and Catalytic Efficiencies of an Oligopeptide Array
- Open Access
An eccentric calpain, CAPN3/p94/calpain-3
- Open Access
- 4 October 2015
- Published by Elsevier in Data in Brief
- Vol. 5, 366-367
Amino acid sequence alignment of vertebrate CAPN3/calpain-3/p94
- 4 October 2015
- Published by Elsevier in Data in Brief
- Vol. 5, 366-367
Open AccessAmino acid sequence alignment of vertebrate CAPN3/calpain-3/p94
- Open Access
- 23 June 2015
- Published by Springer Nature in Nature Communications
- Vol. 6 (1) , 7484
Thymoproteasomes produce unique peptide motifs for positive selection of CD8+ T cells
Positive selection in the thymus provides low-affinity T-cell receptor (TCR) engagement to support the development of potentially useful self-major histocompatibility complex class I (MHC-I)-restricted T cells. Optimal positive selection of CD8+ T cells requires cortical thymic epithelial cells that express β5t-containing thymoproteasomes (tCPs). However, how tCPs govern positive selection is unclear. Here we show that the tCPs produce unique cleavage motifs in digested peptides and in MHC-I-associated peptides. Interestingly, MHC-I-associated peptides carrying these tCP-dependent motifs are enriched with low-affinity TCR ligands that efficiently induce the positive selection of functionally competent CD8+ T cells in antigen-specific TCR-transgenic models. These results suggest that tCPs contribute to the positive selection of CD8+ T cells by preferentially producing low-affinity TCR ligand peptides.
- 23 June 2015
- Published by Springer Nature in Nature Communications
- Vol. 6 (1) , 7484
Open AccessThymoproteasomes produce unique peptide motifs for positive selection of CD8+ T cells
Positive selection in the thymus provides low-affinity T-cell receptor (TCR) engagement to support the development of potentially useful self-major histocompatibility complex class I (MHC-I)-restricted T cells. Optimal positive selection of CD8+ T cells requires cortical thymic epithelial cells that express β5t-containing thymoproteasomes (tCPs). However, how tCPs govern positive selection is unclear. Here we show that the tCPs produce unique cleavage motifs in digested peptides and in MHC-I-associated peptides. Interestingly, MHC-I-associated peptides carrying these tCP-dependent motifs are enriched with low-affinity TCR ligands that efficiently induce the positive selection of functionally competent CD8+ T cells in antigen-specific TCR-transgenic models. These results suggest that tCPs contribute to the positive selection of CD8+ T cells by preferentially producing low-affinity TCR ligand peptides.
- Open Access
- 29 April 2015
- Published by Springer Nature in Nature Communications
- Vol. 6 (1) , 7035
Ablation of the p16INK4a tumour suppressor reverses ageing phenotypes of klotho mice
The p16INK4a tumour suppressor has an established role in the implementation of cellular senescence in stem/progenitor cells, which is thought to contribute to organismal ageing. However, since p16INK4a knockout mice die prematurely from cancer, whether p16INK4a reduces longevity remains unclear. Here we show that, in mutant mice homozygous for a hypomorphic allele of the α-klotho ageing-suppressor gene (klkl/kl), accelerated ageing phenotypes are rescued by p16INK4a ablation. Surprisingly, this is due to the restoration of α-klotho expression in klkl/kl mice and does not occur when p16INK4a is ablated in α-klotho knockout mice (kl−/−), suggesting that p16INK4a is an upstream regulator of α-klotho expression. Indeed, p16INK4a represses α-klotho promoter activity by blocking the functions of E2Fs. These results, together with the observation that the expression levels of p16INK4a are inversely correlated with those of α-klotho throughout ageing, indicate that p16INK4a plays a previously unrecognized role in downregulating α-klotho expression during ageing.
- 29 April 2015
- Published by Springer Nature in Nature Communications
- Vol. 6 (1) , 7035
Open AccessAblation of the p16INK4a tumour suppressor reverses ageing phenotypes of klotho mice
The p16INK4a tumour suppressor has an established role in the implementation of cellular senescence in stem/progenitor cells, which is thought to contribute to organismal ageing. However, since p16INK4a knockout mice die prematurely from cancer, whether p16INK4a reduces longevity remains unclear. Here we show that, in mutant mice homozygous for a hypomorphic allele of the α-klotho ageing-suppressor gene (klkl/kl), accelerated ageing phenotypes are rescued by p16INK4a ablation. Surprisingly, this is due to the restoration of α-klotho expression in klkl/kl mice and does not occur when p16INK4a is ablated in α-klotho knockout mice (kl−/−), suggesting that p16INK4a is an upstream regulator of α-klotho expression. Indeed, p16INK4a represses α-klotho promoter activity by blocking the functions of E2Fs. These results, together with the observation that the expression levels of p16INK4a are inversely correlated with those of α-klotho throughout ageing, indicate that p16INK4a plays a previously unrecognized role in downregulating α-klotho expression during ageing.
- 20 April 2015
- Published by S. Karger AG
- p. 35-46
3 A Novel Calpain Species, n-Calpain, Active at nM Levels of Calcium?
- 20 April 2015
- Published by S. Karger AG
- p. 35-46
3 A Novel Calpain Species, n-Calpain, Active at nM Levels of Calcium?